Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
DVHA reports $287 million drug spend, sets aside $4.5 million for new high-cost therapies
Summary
DVHA told lawmakers it manages roughly $287 million in drug spending across state programs, reported a 4% decline in gross drug spend last year and included a $4.5 million FY26 request to cover new, very high-cost therapies not in the current baseline.
Department of Vermont Health Access officials told the House Appropriations Committee that the agency manages about $287 million in gross drug spending across publicly funded programs and reported a roughly 4% decrease in gross spend in the most recent fiscal year.
Stephanie Barrett, DVHA chief financial officer, told the committee the total managed drug spend covers Medicaid and other public programs and that physician‑administered drugs sometimes fall outside the Medicaid system’s reporting. Barrett said DVHA recorded a decrease of about 4%…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
